Published in J Immunol Res on March 09, 2014
Antibody-Dependent NK Cell Activation Is Associated with Late Kidney Allograft Dysfunction and the Complement-Independent Alloreactive Potential of Donor-Specific Antibodies. Front Immunol (2016) 0.77
Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy. Kidney Int (2016) 0.76
Renal allograft rejection: pieces of the puzzle. J Am Soc Nephrol (2014) 0.75
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet (2012) 4.85
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol (2002) 3.34
Identifying specific causes of kidney allograft loss. Am J Transplant (2008) 2.77
Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol (2007) 2.64
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Renal transplantation in patients with pre-transplant donor-specific antibodies and negative flow cytometry crossmatches. Am J Transplant (2007) 2.28
Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant (2009) 2.27
Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant (2012) 2.10
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant (2011) 1.98
The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant (2011) 1.98
A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant (2012) 1.93
Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplantation (2008) 1.92
Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant (2005) 1.79
Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int (2011) 1.73
Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol (2001) 1.72
Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int (2009) 1.68
Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant (2011) 1.66
Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol (2007) 1.64
International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int (2001) 1.59
Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant (2004) 1.54
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant (2009) 1.52
Comparative study on signal transduction in endothelial cells after anti-a/b and human leukocyte antigen antibody reaction: implication of accommodation. Transplantation (2012) 1.49
Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol (2009) 1.48
Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant (2007) 1.44
Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant (2007) 1.40
Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. J Heart Lung Transplant (2010) 1.35
Anti-MHC class I antibody activation of proliferation and survival signaling in murine cardiac allografts. J Immunol (2008) 1.33
Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant (2005) 1.32
Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant (2012) 1.31
HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol (2008) 1.31
Transplant glomerulopathy. Am J Transplant (2008) 1.29
The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol (2012) 1.29
De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation (2012) 1.28
De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant (2011) 1.22
Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant (2001) 1.20
Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant (2011) 1.17
Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int (2005) 1.17
Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation (2003) 1.14
Transplant glomerulopathy: ultrastructural abnormalities occur early in longitudinal analysis of protocol biopsies. Am J Transplant (2007) 1.11
Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol (2008) 1.11
Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant (2008) 1.11
Transplant glomerulopathy: evolution of morphologically distinct changes. Kidney Int (1985) 1.09
Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant (2006) 1.05
Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol (2012) 1.05
Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int (2004) 1.04
Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol (2011) 1.01
The glomerular endothelium: new insights on function and structure. Curr Opin Nephrol Hypertens (2012) 0.99
Early ultrastructural changes in renal allografts: correlation with antibody-mediated rejection and transplant glomerulopathy. Am J Transplant (2011) 0.98
Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Am J Transplant (2012) 0.98
Ultrastructure of transplant glomerulopathy. Histopathology (1980) 0.94
Sensitized renal transplant recipients: current protocols and future directions. Nat Rev Nephrol (2010) 0.94
Determinants of the complement-fixing ability of recipient presensitization against HLA antigens. Transplantation (2007) 0.93
Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transpl Immunol (2009) 0.91
Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J Am Soc Nephrol (2011) 0.91
Characterization of the endothelial cell cytoskeleton following HLA class I ligation. PLoS One (2012) 0.91
The early course of kidney allograft rejection: defining the time when rejection begins. Am J Transplant (2009) 0.91
Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy. Hum Immunol (2011) 0.90
Determinants of long-term graft outcome in transplant glomerulopathy. Transplantation (2010) 0.89
Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant (2010) 0.89
Clinical significance of the distribution of C4d deposits in different anatomic compartments of the allograft kidney. Mod Pathol (2008) 0.85
Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen. Exp Clin Transplant (2012) 0.85
HLA class I-mediated stress fiber formation requires ERK1/2 activation in the absence of an increase in intracellular Ca2+ in human aortic endothelial cells. Am J Physiol Cell Physiol (2012) 0.84
Treatment of symptomatic transplant glomerulopathy with rituximab. Transpl Int (2009) 0.83
Endothelial molecules decipher the mechanisms and functional pathways in antibody-mediated rejection. Hum Immunol (2012) 0.82
Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant (2010) 0.81
Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report. Clin Transpl (2010) 0.81
Transplant glomerulopathy as a cause of late graft loss. Am J Kidney Dis (2000) 0.81
Human leukocyte antigen-specific antibodies and gamma-interferon stimulate human microvascular and glomerular endothelial cells to produce complement factor C4. Transplantation (2012) 0.80
Clinical significance of allograft glomerulopathy. Kidney Int Suppl (1993) 0.80
Transplant glomerulopathy: clinical course and factors relating to graft survival. Transplant Proc (2012) 0.79
HLA class I: an unexpected role in integrin β4 signaling in endothelial cells. Hum Immunol (2012) 0.78
Novel immunotherapeutic approaches to improve rates and outcomes of transplantation in sensitized renal allograft recipients. Discov Med (2012) 0.77
Picking transplant glomerulopathy out of the CAN: evidence from a clinico-pathological evaluation. BMC Nephrol (2012) 0.76